EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice

Mayara Mattos iD, Carolina Q Sacramento iD, André C Ferreira iD, Natalia Fintelman-Rodrigues iD, Filipe S Pereira-Dutra iD, Caroline Souza de Freitas iD, João S M Gesto iD, Jairo R Temerozo iD, Aline de Paula Dias Da Silva, Mariana T G Moreira, Rafael S C Silva, Gabriel P E Silveira und 9 weitere

Viruses · 2024

DOI: 10.3390/v16121856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Mayara Mattos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil. Hauptthemen laut MEDLINE: Pyrrolidines, Valine, Imidazoles, Mice, Transgenic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Council for Scientific and Technological Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) still causes death in elderly and immunocompromised individuals, for whom the sustainability of the vaccine response may be limited. Antiviral treatments, such as remdesivir or molnupiravir, have demonstrated limited clinical efficacy. Nirmatrelvir, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) major protease inhibitor, is clinically effective but has been associated with viral rebound and antiviral resistance. It is thus necessary to study novel and repurposed antivirals for the treatment of COVID-19. We previously demonstrated that daclatasvir (DCV), an inhibitor of the hepatitis C virus (HCV) NS5A protein, impairs SARS-CoV-2 replication by targeting viral RNA polymerase and exonuclease, but the doses of DCV used to inhibit the new coronavirus are greater than the standard human plasma exposure for hepatitis C. Because any potential use of DCV against SARS-CoV-2 would be shorter than that reported here and short-term toxicological studies on DCV show that higher doses are tolerable, we searched for doses of DCV that could protect transgenic mice expressing the human ACE2 receptor (K18-hACE-2) from lethal challenge with SARS-CoV-2. We found that a dose of 60 mg/kg/day provides this protection by reducing virus replication and virus-induced lung insult. This dose is tolerable in different animal models. Taken together, our data provide preclinical evidence that can support phase I clinical trials to confirm the safety, tolerability, and pharmacokinetics of new doses of daclatasvir for a short duration in humans to further advance this compound’s utility against COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolidinesValineImidazolesMice, TransgenicCarbamatesAntiviral AgentsSARS-CoV-2COVID-19Angiotensin-Converting Enzyme 2COVID-19 Drug TreatmentVirus ReplicationAnimalsMiceHumansDisease Models, AnimalFemale

Stichwörter der Autor:innen

K18-hACE2 miceSARS-CoV-2anti-HCV drugserror proneexonuclease

Substanzen

PyrrolidinesdaclatasvirValineImidazolesCarbamatesAntiviral AgentsAngiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.
  • National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-…
  • Laboratório de Pesquisas Pré-Clínicas, Departamento de Ciências Biológicas, Universidade Iguaçu, Nova Iguaçu 26275-580, RJ, Brazil.
  • SESI Innovation Center for Occupational Health, Rio de Janeiro 22735-280, RJ, Brazil.
  • Laboratório de Pesquisas Sobre o Timo, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.
  • National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.

ORCID-Profile: Mayara Mattos, Carolina Q Sacramento, André C Ferreira, Natalia Fintelman-Rodrigues, Filipe S Pereira-Dutra, Caroline Souza de Freitas, João S M Gesto, Jairo R Temerozo, Douglas P Pinto, Dumith Chequer Bou-Habib, Patrícia T Bozza

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Council for Scientific and Technological Development
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • Coordenação de Aperfeicoamento de Pessoal de Nível Superior
  • National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIAID-NIH)
  • Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Mattos, M., Sacramento, C. Q., Ferreira, A. C., Fintelman-Rodrigues, N., Pereira-Dutra, F. S., de Freitas, C. S., Gesto, J. S. M., Temerozo, J. R., Silva, A. P. D. D., Moreira, M. T. G., Silva, R. S. C., Silveira, G. P. E., Pinto, D. P., Pereira, H. M., Fonseca, L. B., Alves Ferreira, M., Blanco, C., Viola, J. P. B., Bou-Habib, D. C., …, & Souza, T. M. L. (2024). Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice. Viruses. https://doi.org/10.3390/v16121856

Vancouver

Mattos M, Sacramento CQ, Ferreira AC, Fintelman-Rodrigues N, Pereira-Dutra FS, de Freitas CS, et al. Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice. Viruses. 2024. doi:10.3390/v16121856

BibTeX
@article{Mattos2024,
  author = {Mattos, Mayara and Sacramento, Carolina Q and Ferreira, André C and Fintelman-Rodrigues, Natalia and Pereira-Dutra, Filipe S and de Freitas, Caroline Souza and Gesto, João S M and Temerozo, Jairo R and Silva, Aline de Paula Dias Da and Moreira, Mariana T G and Silva, Rafael S C and Silveira, Gabriel P E and Pinto, Douglas P and Pereira, Heliana M and Fonseca, Laís B and Alves Ferreira, Marcelo and Blanco, Camilla and Viola, João P B and Bou-Habib, Dumith Chequer and Bozza, Patrícia T and Souza, Thiago Moreno L},
  title = {Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16121856}
}
Kostenlos starten →